pumecitinib nasal spray (PG-011 nasal spray)
/ Prime Gene Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 27, 2025
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
(clinicaltrials.gov)
- P2 | N=160 | Active, not recruiting | Sponsor: Prime Gene Therapeutics Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jan 2026 ➔ May 2026
Enrollment closed • Trial completion date • Allergic Rhinitis • Immunology • Inflammation
April 02, 2025
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults with Moderate to Severe Seasonal Allergic Rhinitis
(ChiCTR)
- P2 | N=160 | Recruiting | Sponsor: Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University
New P2 trial • Allergic Rhinitis • Immunology • Inflammation
February 20, 2025
Pumecitinib: A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
(clinicaltrials.gov)
- P2 | N=160 | Not yet recruiting | Sponsor: Prime Gene Therapeutics Co., Ltd.
New P2 trial • Allergic Rhinitis • Immunology • Inflammation
1 to 3
Of
3
Go to page
1